Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NASDAQ:BTX - BioTime Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.81
-0.04 (-4.71 %)
(As of 01/24/2020 01:44 AM ET)
Today's Range
$0.80
Now: $0.81
$0.85
50-Day Range
$0.92
MA: $0.96
$0.99
52-Week Range
$0.66
Now: $0.81
$2.81
Volume590,857 shs
Average Volume719,479 shs
Market Capitalization$121.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTX
CUSIPN/A
CIKN/A
Phone510-521-3390

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$121.21 million
Next Earnings DateN/A
OptionableOptionable

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

BioTime (NASDAQ:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the NASDAQ under the ticker symbol "BTX."

What is the consensus analysts' recommendation for BioTime?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime.

Has BioTime been receiving favorable news coverage?

Media stories about BTX stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BioTime earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for BioTime.

Who are some of BioTime's key competitors?

What other stocks do shareholders of BioTime own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTime investors own include CVS Health (CVS), AT&T (T), ADMA Biologics (ADMA), Anavex Life Sciences (AVXL), Novavax (NVAX), Opko Health (OPK), Roku (ROKU), SCYNEXIS (SCYX), Selecta Biosciences (SELB) and Soligenix (SNGX).

Who are BioTime's key executives?

BioTime's management team includes the folowing people:
  • Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 60)
  • Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)
  • Mr. Brian M. Culley, CEO , Pres & Director (Age 48)
  • Ms. Brandi L. Roberts, CFO & Sr. VP of Fin. (Age 45)

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $0.81.

How big of a company is BioTime?

BioTime has a market capitalization of $121.21 million. View Additional Information About BioTime.

What is BioTime's official website?

The official website for BioTime is http://www.biotimeinc.com/.

How can I contact BioTime?

The company can be reached via phone at 510-521-3390.


MarketBeat Community Rating for BioTime (NASDAQ BTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  20 (Vote Underperform)
Total Votes:  40
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel